Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQ789Z)

Drug Name
8H9 Drug Info
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
164575500
TTD Drug ID
DMQ789Z

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tenascin (TNC) TTUCPMY TENA_HUMAN Not Available [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tenascin (TNC) DTT TNC 4.365 6.758 6.7 6.126
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tenascin (TNC) DTT TNC 2.41E-162 2.68 3.01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01502917) Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01099644) Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum. U.S. NationalInstitutes of Health.
3 In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24.